IPP Bureau
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
By IPP Bureau - July 02, 2022
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
By IPP Bureau - July 02, 2022
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
NITI Aayog releases a compendium of Ayush-based practices
By IPP Bureau - July 02, 2022
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
Biosynth Carbosynth expands peptide offering with acquisition of Pepscan
By IPP Bureau - July 01, 2022
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
Jubilant HollisterStier announces CAD 100 mn for Montreal facility
By IPP Bureau - July 01, 2022
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Lupin receives approval from USFDA for Paliperidone extended-release tablets
By IPP Bureau - July 01, 2022
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Zydus receives final approval from USFDA for Lacosamide injection
By IPP Bureau - July 01, 2022
Lacosamide Injection is used to treat partial-onset seizures.
H Clinical adds commercial home health capabilities for pharma industry
By IPP Bureau - July 01, 2022
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
By IPP Bureau - July 01, 2022
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar
By IPP Bureau - July 01, 2022
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
By IPP Bureau - July 01, 2022
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
NADMED brings first CE-marked NAD+ analysis kit to the market
By IPP Bureau - June 30, 2022
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
India’s first mRNA vaccine from Gennova gets DCGI approval
By IPP Bureau - June 30, 2022
It is a two dose vaccine to be administered intramuscularly at 28 days apart
TTK Healthcare launches e-Superstore - 'Love Depot'
By IPP Bureau - June 30, 2022
LoveDepot.com addresses this gap that is yawning in the market
Experts call for “Disability Inclusive Health Care System” to address health inequity
By IPP Bureau - June 30, 2022
We must try to make the health care system more accessible for people with disabilities
